Zimmer Biomet (ZBH) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Zimmer Biomet (NYSE: ZBH) in the last few weeks:

• 2/20/2026 – Zimmer Biomet is now covered by William Blair. They set a “market perform” rating on the stock.
• 2/14/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/12/2026 – Zimmer Biomet had its price target lowered by Barclays PLC from $104.00 to $100.00. They now have an “underweight” rating on the stock.
• 2/11/2026 – Zimmer Biomet had its “sell” rating reaffirmed by UBS Group AG. They now have a $89.00 price target on the stock.
• 2/11/2026 – Zimmer Biomet had its “buy” rating reaffirmed by Citigroup Inc..
• 2/11/2026 – Zimmer Biomet had its price target raised by Citigroup Inc. from $94.00 to $98.00. They now have a “neutral” rating on the stock.
• 2/11/2026 – Zimmer Biomet had its price target raised by Wells Fargo & Company from $93.00 to $98.00. They now have an “equal weight” rating on the stock.
• 2/10/2026 – Zimmer Biomet had its “buy” rating reaffirmed by BTIG Research. They now have a $112.00 price target on the stock.
• 2/10/2026 – Zimmer Biomet had its “hold” rating reaffirmed by Needham & Company LLC.
• 1/28/2026 – Zimmer Biomet had its price target lowered by UBS Group AG from $88.00 to $86.00. They now have a “sell” rating on the stock.
• 1/26/2026 – Zimmer Biomet was upgraded by TD Cowen from “hold” to “buy”.
• 1/21/2026 – Zimmer Biomet had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 1/17/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/9/2026 – Zimmer Biomet had its price target raised by Sanford C. Bernstein from $97.00 to $99.00. They now have a “market perform” rating on the stock.
• 1/9/2026 – Zimmer Biomet was downgraded by The Goldman Sachs Group, Inc. from “neutral” to “sell”. They now have a $93.00 price target on the stock.
• 1/8/2026 – Zimmer Biomet had its “buy” rating reaffirmed by BTIG Research. They now have a $112.00 price target on the stock.
• 1/5/2026 – Zimmer Biomet was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $120.00 price target on the stock, up from $94.00.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.